|Oxurion (former Thrombogenics)||Global Head of Business Development and Licensing||Belgium|
What roles do academic institutions or TTOs play as shareholders in spinoffs?
Grégoire is currently Global Head of Business Development and Licensing for Oxurion NV (Euronext: OXUR), a leading biopharmaceutical company specialized in developing innovative treatments for retinal disorders with high unmet needs such as Diabetic Retinopathy. Grégoire has 15 years of international experience in corporate development, venture financing, in & out-licensing, alliance management and new products development. He is also a Certified Licensing Professional (CLP).
He started his career as a biotech analyst in the Life Science Venture Capital team of AXA Private Equity (now Ardian) before joining Flamel Technologies (now Avadel Nasdaq: AVDL) where he was instrumental to several key partnerships and licensing agreements with large pharmaceutical companies. In 2012, he joined Germany, Aachen-based Grünenthal GmbH, a global pharmaceutical group where he led significant in- as well as out-licensing transactions in the field of pain.
Grégoire holds a Master degree in biotechnologies from ESIEE Paris, a Master degree in International Finance from IAE Graduate School of Management and a Global Executive MBA from INSEAD (Singapore/Fontainebleau).